LOTTE BIOLOGICS was established in 2022, and is headquartered in Seoul, South Korea. With 500+ employees, LOTTE BIOLOGICS is now entering the pharmaceutical industry as a CDMO company with the acquisition of Bristol-Myers Squibb’s Syracuse biologics manufacturing site.
The Syracuse site offers drug substance manufacturing services with a total of 35,000L of production bioreactor capacity (7 x 5kL bioreactors) utilizing stainless steel bioreactors, analytical QC testing laboratories, and warehouse facilities. The site is fully GMP operational with clinical and commercial capabilities. As of today, the site has received 60+ approvals worldwide from the FDA, EMA, PMDA, and MFDS.
By 2030, LOTTE BIOLOGICS plans to build 3 mega plants in South Korea. Each plant will have 8 stainless steel bioreactors with 15,000L capacities for large-scale commercial operations, alongside multiple 2,000L single-use bioreactors to accommodate the clinical needs. The groundbreaking is expected to take place in 2023. Altogether, the plants will have a total manufacturing volume of 360,000L or more in bioreactor capacity.
By providing innovative medicines to patients, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry.
